Medical morphine is prescribed for conditions such as arthritis, cancer, and cardiovascular disorders. The increasing use of painkillers in combating these disorders is the main driver for the global medical morphine market. Cardiovascular disorders are among the deadliest diseases of the modern age, with the American Heart Association reporting that one in three deaths in the U.S. in 2014 was due to cardiovascular disorders. Cardiovascular diseases claimed over 800,000 lives in the U.S. in 2014, demonstrating their growing prevalence. As a result, medication to counter cardiovascular pain is becoming ever more prevalent. This is likely to be a major driver for the global medical morphine market, as pollution and lifestyle factors are likely to further drive the prevalence of cardiovascular diseases across the world in the coming years.
Market Research Future (MRFR) has announced the release of a new market research report. The report analyzes the global Medical Morphine Market Size and provides readers with forecasts for the 2017-2023 forecast period. According to the report, the global medical morphine market is expected to rise at a CAGR of 7.5% over the 2017-2023 forecast period.
On the other hand, the risk of morphine addiction is likely to hinder the growth of the global medical morphine market over the forecast period. Morphine is an opioid and is thus a highly restricted substance. Opioid addiction is one of the biggest problems facing the developed world at present, but since opioids are the only naturally available painkillers known to man, their use is still rendered necessary. This has led to opioid addiction emerging as a serious threat to human wellbeing in the developed world over the last few decades. This is likely to lead to strict restrictions on the medical morphine market, curtailing its growth.
Mallinckrodt Pharmaceuticals, Alcaliber S.A, Purdue Pharma L.P., Pfizer Inc., Johnson Matthey Fine Chemicals, Sun Pharmaceutical Industries Ltd., Verve Health Care Ltd., Taj Pharmaceuticals Limited, NORTHEAST PHARM, and MANUS AKTTEVA BIOPHARMA LLP.
· The report segments the global Medical Morphine Market by route of administration, distribution channel, application, end use, and region.
· By route of administration, the global medical morphine market is segmented into oral and injected medical morphine.
· Based on distribution channel, the medical morphine market is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others.
· Based on application, the medical morphine market is segmented into cancer, arthritis, kidney stones, myocardial infarction, diarrhea, and others.
· By end use, the medical morphine market is segmented into home care, hospitals and clinics, and ambulatory surgical centers.
Geographically, the report segments the global medical morphine market into the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa. The Americas segment is further segmented into North and South America, while the Europe segment is further divided into Western and Eastern Europe.
Access Full Report Details:https://www.marketresearchfuture.com/reports/medical-morphine-market-6084
The Americas and Europe collectively account for more than 75% of the global medical morphine market and are likely to remain the largest regional segment of the market due to the high geriatric population in the region. Geriatric care is a major issue in countries such as the U.S., Canada, the UK, and France, which is likely to enable strong prospects for the medical morphine market in these regions over the forecast period. Increasing prevalence of cardiovascular diseases is likely to enable strong growth of the APAC market for medical morphine over the forecast period.
Related Infographics are:
Cardiac Implants Market Research Report - Global Forecast till 2023
Breast Implants Market Research Report â€“ Forecast to 2023